@article{10.11648/j.ejcbs.20220804.12,
  author = {Bisi Bright and Patrick Sobande and Temitope Alonge and Chinedum Peace Babalola and Adewale Abdul-Semiu Musa-Olomu and Wael Ali and Olayinka Kotila and Niyi Fajimi and Ewaoche Sunday Itodo and Seun Falayi and David Ajayi and Adebola Olatunji and Toyin Adesope and Fidelis Ojeblenu and Modupe Ologunagba and Aduh and Rilwan Rotinwa and Gbenga Odunfa and Arinzechchukwu Chukwurah and Sylvester Adeyemi},
  title = {Telling the COVID-19 Story – An Overview of Our COVID-19 Study Protocols and Research at Livewell Initiative LWI and Global Public Health University GPHU},
  journal = {European Journal of Clinical and Biomedical Sciences},
  volume = {8},
  number = {4},
  pages = {62-70},
  doi = {10.11648/j.ejcbs.20220804.12},
  url = {https://doi.org/10.11648/j.ejcbs.20220804.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ejcbs.20220804.12},
  abstract = {A study by LiveWell Initiative’s Global Public Health University (GPHU) in collaboration with frontline healthcare workers in Nigeria tested 4-Aminoquinolines as prophylaxis for COVID-19 in Nigeria, recorded some significant level of success. Quinine crosses the blood-brain barrier into the alveoli which gives it an added advantage over chloroquine and hydroxychloroquine in COVID-19 and picks up where CQ/ HCQ stop. The study was a random Physician – Patient Trials at the discretion of Prescribing Clinicians and Clinical Researchers, they are as recommended. The preliminary data analyzed using Microsoft excel, were from 123 study participants (110 used as prophylaxis and 23 as treatment). CQ/HCQ is also relevant for Inpatient care as the 11 Laboratory Tested Positive Patients placed on admission at the COVID-19 Isolation Center who were treated with CQ are all fully recovered, up to 6 weeks post-lockdown with no relapse, and having tested negative twice post treatment. Quinine works in advanced COVID-19 as the Single Laboratory Tested Positive client on the ventilator, were fully recovered after Treatment with I.V. Quinine and is still symptom free 6 weeks post-lockdown. The tests were re-run through the second, third wave, Delta and Omicron stages. The further results will be discussed in subsequent papers scheduled for publication.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Telling the COVID-19 Story – An Overview of Our COVID-19 Study Protocols and Research at Livewell Initiative LWI and Global Public Health University GPHU
AU  - Bisi Bright
AU  - Patrick Sobande
AU  - Temitope Alonge
AU  - Chinedum Peace Babalola
AU  - Adewale Abdul-Semiu Musa-Olomu
AU  - Wael Ali
AU  - Olayinka Kotila
AU  - Niyi Fajimi
AU  - Ewaoche Sunday Itodo
AU  - Seun Falayi
AU  - David Ajayi
AU  - Adebola Olatunji
AU  - Toyin Adesope
AU  - Fidelis Ojeblenu
AU  - Modupe Ologunagba
AU  - Aduh
AU  - Rilwan Rotinwa
AU  - Gbenga Odunfa
AU  - Arinzechchukwu Chukwurah
AU  - Sylvester Adeyemi
Y1  - 2022/07/28
PY  - 2022
N1  - https://doi.org/10.11648/j.ejcbs.20220804.12
DO  - 10.11648/j.ejcbs.20220804.12
T2  - European Journal of Clinical and Biomedical Sciences
JF  - European Journal of Clinical and Biomedical Sciences
JO  - European Journal of Clinical and Biomedical Sciences
SP  - 62
EP  - 70
PB  - Science Publishing Group
SN  - 2575-5005
UR  - https://doi.org/10.11648/j.ejcbs.20220804.12
AB  - A study by LiveWell Initiative’s Global Public Health University (GPHU) in collaboration with frontline healthcare workers in Nigeria tested 4-Aminoquinolines as prophylaxis for COVID-19 in Nigeria, recorded some significant level of success. Quinine crosses the blood-brain barrier into the alveoli which gives it an added advantage over chloroquine and hydroxychloroquine in COVID-19 and picks up where CQ/ HCQ stop. The study was a random Physician – Patient Trials at the discretion of Prescribing Clinicians and Clinical Researchers, they are as recommended. The preliminary data analyzed using Microsoft excel, were from 123 study participants (110 used as prophylaxis and 23 as treatment). CQ/HCQ is also relevant for Inpatient care as the 11 Laboratory Tested Positive Patients placed on admission at the COVID-19 Isolation Center who were treated with CQ are all fully recovered, up to 6 weeks post-lockdown with no relapse, and having tested negative twice post treatment. Quinine works in advanced COVID-19 as the Single Laboratory Tested Positive client on the ventilator, were fully recovered after Treatment with I.V. Quinine and is still symptom free 6 weeks post-lockdown. The tests were re-run through the second, third wave, Delta and Omicron stages. The further results will be discussed in subsequent papers scheduled for publication.
VL  - 8
IS  - 4
ER  - 

Copy | Download